How Do Chinese Regulations Differentiate between Peptide Drugs and Delivery Devices for Oversight?
China's NMPA classifies a product by its primary therapeutic action, regulating it as a drug if the peptide is key, or a device if the delivery mechanism is.
HRTioAugust 4, 2025